ZIMLAB Zim Laboratories Q1 FY27 results (Apr–Jun 2026) and concall
Zim Laboratories reported a strong 31.2% YoY revenue growth in Q1 FY27, reaching INR 942 million, driven by resilient exports and contributions from its innovative product portfolio. However, profitability was impacted, with EBITDA margin at 3.7% and a net loss of INR 40 million, due to strategic investments and higher operating costs. The company is awaiting the final EU-GMP inspection report, which is critical for unlocking growth in regulated markets, and expects to start EU supplies by Q4 FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 30.3%, net profit down 129.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 95 | 109 | 71 | 88 −1% | 108 +13% | 103 −5% | 93 +30% |
| EBITDA | 8 | 12 | 15 | 4 | 6 −26% | 13 +6% | 7 −57% | 2 −45% |
| Net profit | 1 | 4 | 5 | -2 | 0 −90% | 4 −2% | 3 −39% | -4 −130% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
